NewGenIvf Group (NASDAQ:NIVF) Stock Rating Lowered by Wall Street Zen

NewGenIvf Group (NASDAQ:NIVF) was downgraded by stock analysts at Wall Street Zen to a “strong sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings restated a “sell (d)” rating on shares of NewGenIvf Group in a research report on Friday, July 24th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

NewGenIvf Group Price Performance

Shares of NASDAQ:NIVF opened at $1.46 on Friday. The stock’s 50-day simple moving average is $23.43 and its two-hundred day simple moving average is $180.01. NewGenIvf Group has a 52-week low of $1.14 and a 52-week high of $22,636.80.

NewGenIvf Group (NASDAQ:NIVF) last issued its quarterly earnings data on Wednesday, October 7th. The company reported ($426.24) earnings per share for the quarter, missing the consensus estimate of $581.76 by ($1,008.00). The firm had revenue of $0.96 million for the quarter, compared to analysts’ expectations of $20.10 million. Equities analysts anticipate that NewGenIvf Group will post 170.68 earnings per share for the current year.

Insider Buying and Selling at NewGenIvf Group

In related news, Director Kong Cheung bought 78,125 shares of the business’s stock in a transaction on Monday, July 27th. The stock was acquired at an average cost of $32.00 per share, with a total value of $2,500,000.00. Following the purchase, the director directly owned 116,319 shares of the company’s stock, valued at $3,722,208. The trade was a 204.55% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 31.80% of the stock is currently owned by company insiders.

About NewGenIvf Group

NewGenIvf Group Limited is a reproductive-healthcare company focused on fertility treatment and assisted reproductive technology. Through its operating businesses, the company provides services intended to help individuals and couples pursue pregnancy, including in vitro fertilization (IVF) and related fertility-care procedures.

Its services may include fertility consultations, laboratory-based embryo procedures, intracytoplasmic sperm injection (ICSI), embryo transfer, fertility preservation, and genetic testing or screening associated with assisted reproduction.